1-4 of 4
W. Allan Alexander, MD
Close
Sort by
Journal Articles

Single 225μg/Kg Dose Treatment with Eptacog Beta (Factor VIIa, Recombinant) Results in Rapid Hemostasis in Joint Bleeds for Persons with Hemophilia Α or Β with Inhibitors: A PERSEPT1 Subset Analysis

Janna M. Journeycake, MD, Cedric Hermans, MDMRCP,PhD, Jonathan M. Ducore, MD MPH, Miguel A. Escobar, MD, Guy Young, MD, Michael Wang, MD, Doris Quon, MD PhD, W Allan Alexander, MD, Ian S Mitchell, PhD, Ahmad Al-Sabbagh, MD, Daniel Bonzo, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 2–3.
https://doi.org/10.1182/blood-2020-136443
Published: 2020
Journal Articles

PERSEPT3: A Phase 3 Clinical Trial to Evaluate the Hemostatic Efficacy of Eptacog Beta (Recombinant Human FVIIa) in Perioperative Care in Subjects with Hemophilia Α or B with Inhibitors

Miguel A. Escobar, MD, Doris Quon, MD PhD, Cindy A. Leissinger, MD, James V Luck, Jr., MD, Ahmad Al-Sabbagh, MD, Daniel Bonzo, PhD, Ian S Mitchell, PhD, W Allan Alexander, MD, Cedric Hermans, MDMRCP,PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 34–36.
https://doi.org/10.1182/blood-2020-136448
Published: 2020
Journal Articles

Favorable Immunologic Response to Recombinant Thrombin Application in Surgery among Subjects with Pre-Existing Antibodies to Bovine Thrombin.

Gregory Moneta, MD, Jeffrey Ballard, MD, Carlton Randleman, MD, Kenneth Renkens, Jr., MD, Neil Singla, MD, W. Allan Alexander, MD
Journal: Blood
Blood (2008) 112 (11): 3390.
https://doi.org/10.1182/blood.V112.11.3390.3390
Published: 2008
Journal Articles

Favorable Immunologic Response Profile to Recombinant Thrombin Application in Surgery: An Integrated Analysis of 8 Clinical Trials

William Chapman, MD, Kenneth Renkens, Jr., MD, Richard Gamelli, MD, FACS, Carlton Randleman, MD, Jeffrey Ballard, MD, W. Allan Alexander, MD
Journal: Blood
Blood (2008) 112 (11): 4088.
https://doi.org/10.1182/blood.V112.11.4088.4088
Published: 2008